Finally, in mantle cell lymphoma (MCL), 20% of patients have high-risk features, namely a high-risk MCL International Prognostic Index (MIPI) score associated with a median OS of 29 months or high-risk molecular features such as TP53 mutations, or refractoriness to Bruton’s tyrosine kinase (BTK) inhibitors [11, 12]. The gene discussed is TP53; the disease is mantle cell lymphoma.